Pierluigi Antonelli

 

Pierluigi Antonelli
President and CEO
Fresenius Kabi

Pierluigi Antonelli is the President and CEO of Fresenius Kabi since March 2023.

Pierluigi Antonelli has extensive operational expertise in the pharmaceutical industry, with a focus on product development, launch of new products in key international markets, business & strategy development, and their implementation. In his previous position, he served as CEO of Angelini Pharma, a company within the Italian Angelini Group specialized in Brain Health and Consumer Health, since 2019. Prior to that, he held senior positions at companies such as Novartis Oncology, Sandoz, Merck & Co, and Bristol-Myers Squibb in the United States and Europe, after working few years in McKinsey & Company. He holds an MBA from Kellogg School of Management and a degree in Economics from L.U.I.S.S..